Skip to main content
logo
Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.01
-0.25 (-3.03%)
At close: Aug 28, 2026, 4:00 PM EDT
8.03
+0.02 (0.25%)
After-hours: Aug 28, 2026, 7:52 PM EDT

Iovance Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-289.52-390.98-372.18-444.04-395.89-342.25
Depreciation & Amortization
44.9847.3248.0733.1321.1413.98
Loss (Gain) From Sale of Assets
0.670.041.79---
Asset Writedown & Restructuring Costs
----0.4-
Loss (Gain) From Sale of Investments
-5.59-7.2-10.26-3.610.476.01
Stock-Based Compensation
46.7261.58109.6362.6384.0269.77
Other Operating Activities
2.9411.1-3-3.41--
Change in Accounts Receivable
-42.18-13.11-69.19-0.15--
Change in Inventory
-12.13-14.21-44.38-10.12--
Change in Accounts Payable
-5.54-6.66-7.844.835.886.98
Change in Other Net Operating Assets
-4.549.71-5.61-1.08-8.7817.58
Operating Cash Flow
-264.18-302.41-352.98-361.82-292.76-227.94
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-32.21-33.84-11.07-22.29-20.43-37.57
Cash Acquisitions
---52.57-212.63--
Investment in Securities
-12.6681.33-32.7779.68276.8837.71
Investing Cash Flow
-44.8747.5-96.41-155.24256.460.13

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----1
Net Debt Issued (Repaid)
-----1
Issuance of Common Stock
294.11307.83403.52465.75192.8238.27
Repurchase of Common Stock
-6.26-7.06-12.86-2.8-2.65-
Financing Cash Flow
287.85300.77390.66462.96190.15239.27

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.441.14-0.54-2.74--
Net Cash Flow
-21.6447.01-59.27-56.84153.8511.46

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-296.4-336.24-364.05-384.11-313.18-265.52
Free Cash Flow Growth
------
Free Cash Flow Margin
-91.21%-127.61%-221.89%-32305.30%--
Free Cash Flow Per Share
-0.72-0.94-1.26-1.63-1.97-1.73
Levered Free Cash Flow
-187.79-162.42-198.76-211.47-173.54-129.35
Unlevered Free Cash Flow
-187.79-162.42-198.76-211.47-173.54-129.35

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
-64.39-24.27-127.02-6.52-2.8924.55
SEC Filings: 10-K · 10-Q